Evicenter
P&T meetings

AXPAXLI (axitinib intravitreal implant)

Neovascular age-related macular degeneration

Also known as OTX-TKI
Manufacturer
Ocular Therapeutix
Last updated
309 sources

Product information and disease descriptionProduct descriptionProduct information

Effect of axitinib intravitreal implant on quality measures

2 evidence topics · 1 source

IRIS Registry QCDR measure IRIS63: exudative AMD gain of visual acuity

“Percentage of patients with a diagnosis of exudative age-related macular degeneration, being treated with anti-VEGF agents, with a gain of 1 Snellen line or more” (opens the source at this quote in a new tab)

“Measure Type: Outcome” (opens the source at this quote in a new tab)

IRIS63 denominator: treatments counted as anti-VEGF agents

“Rate 1: All patients aged 50 years of older with a diagnosis of exudative age-related macular degeneration and documentation of laterality (OD, OS, OU) with 5 or more treatments with Anti-VEGF Agents over the reporting year.” (opens the source at this quote in a new tab)

“Ranibizumab (Lucentis®) injections (CPT: 67028 and HCPCS: J2778) Aflibercept (EYLEA®) injections (CPT: 67028 and HCPCS: J0178)” (opens the source at this quote in a new tab)

Product-specific effect on quality measures

No evidence found.